Business Review

Strong growth in new business lines launched - Oncology Day Care, Max Labs and Max@Home

Gross Revenue and Average Revenue per Occupied Bed

Steady growth in Revenue per occupied bed

EBIDTA and EBIDTA Margin

Till Q3 FY 2018, MHC’s performance was as per plan, and in line with peers. However, dramatic changes in the external environment affected its financial trajectory in the final quarter.

Bed Occupancy

Maintained healthy occupancy levels despite bed addition momentum

Revenue Split (%)

Focus on Oncology, Neurology and Renal increasing

2,882

Doctors

4,756

Nurses

4,849

other trained personnel

14

hospitals across North India

4.2

Million patients

Patients from over 80 countries

Reported profit of 23 Crore in FY 18 vs Marginal loss of 4 Crore in FY 17

Gross Written Premium

Revenue growth led by robust growth in new sales as well as renewals

Lives in Force**

Total lives covered, including rural sector, increase to 24 lakh

B2C Claims Ratio

Stability in Claims Ratio driven by high quality of portfolio

Premium Per Life (B2C,  )

Average premium realisation increases 14% driven by growth in share of Gold and Platinum products